Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODYGY: SPVN06 Gene Therapy in Rod-Cone Dystrophy
NCT05748873Phase 2Active, not recruiting
- Sponsor
- SparingVision
- Start
- Apr 2023
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of SPVN06 in retinitis pigmentosa (RP), sponsored by SparingVision. Started Apr 2023; status: active, not recruiting.
02
Drugs
SPVN06
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05748873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748873.